Local Use of Dexamethasone in the Treatment of Ocular Myasthenia Gravis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038863

Enrollment

Unknown

Registered

2020-10-07

Start date

2016-08-24

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Myasthenia Gravis

Interventions

Local injection of hormone:Local injection of hormone

Eligibility

Sex/Gender

All

Age

4 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with ocular myasthenia gravis who visited our hospital from August 2016 to August 2019, diagnosed according to typical symptoms and signs and neostigmine test.

Exclusion criteria

Exclusion criteria: Those with systemic symptoms (with hypothyroidism below the neck), who are not supportive of the treatment plan, are unable to complete the follow-up on time.

Design outcomes

Primary

Measure	Time frame
Squint degree;Palpebral margin activity;eye movement;	—

Countries

China

Contacts

Public ContactMinghua Shi

Wuhan Aier Eye Hospital (Hanyang)

13995559689@163.com+86 13995559689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026